You are here

Takeda

Shire gears up to battle Allergan's Linzess with new constipation drug Motegrity

Shire gears up to battle Allergan's Linzess with new constipation drug Motegrity

Fierce Pharma

chronic idiopathic constipation

Flag link:

Eisai, Takeda and GARDP hunt for new antibiotics

Eisai, Takeda and GARDP hunt for new antibiotics

Pharmaforum

Flag link:

Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design

Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design

Xtalks

clinical trials

Multiple Myeloma

adaptive trial design

Flag link:

What do Martin Shkreli, Gilead and Takeda have in common? They all figure prominently in the new top-20 list of the world’s most expensive drugs

What do Martin Shkreli, Gilead and Takeda have in common? They all figure prominently in the new top-20 list of the world’s most expensive drugs

Endpoints

Gilead Sciences

Flag link:

A last-ditch effort to derail Takeda’s $62B Shire buyout goes down in flames

A last-ditch effort to derail Takeda’s $62B Shire buyout goes down in flames

Endpoints

Flag link:

Takeda Acquisition Of Shire May Bode Well For R&D Staff

Takeda Acquisition Of Shire May Bode Well For R&D Staff

Forbes

Flag link:

Takeda ready to dismiss assets for a total $10bn

Takeda ready to dismiss assets for a total $10bn

GoinPharma

Flag link:

ASH: Takeda maintenance data sets up Ninlaro for new myeloma nod

ASH: Takeda maintenance data sets up Ninlaro for new myeloma nod

Fierce Pharma

Multiple Myeloma

Flag link:

Takeda could rack up $10B in selloffs after controversial Shire buyout: report

Takeda could rack up $10B in selloffs after controversial Shire buyout: report

Fierce Pharma

Flag link:

A Small Group of Pharma Companies Is Making the Bulk of Medicines Necessary for Developing Countries

A Small Group of Pharma Companies Is Making the Bulk of Medicines Necessary for Developing Countries

BioSpace

developing countries

Flag link:

Takeda clears final regulatory hurdle to completing its $62B Shire deal. Now only one obstacle remains

Takeda clears final regulatory hurdle to completing its $62B Shire deal. Now only one obstacle remains

Endpoints

Flag link:

Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years

Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years

BioSpace

Ariad Pharmaceuticals

Boehringer Ingelheim

Bristol-Myers Squibb

Puma Biotechnology

Flag link:

Takeda investors mount last-minute effort to stymie Shire deal: FT

Takeda investors mount last-minute effort to stymie Shire deal: FT

Fierce Pharma

Flag link:

With the $62B Shire buyout on track, Takeda plans to debut the newly merged company at JPMorgan

With the $62B Shire buyout on track, Takeda plans to debut the newly merged company at JPMorgan

Endpoints

Christophe Weber

Flag link:

Exclusive: Takeda to win EU approval for US$62 billion Shire deal - sources

Exclusive: Takeda to win EU approval for US$62 billion Shire deal - sources

Channel News Asia

Flag link:

Takeda CEO confident about Shire merger

Takeda CEO confident about Shire merger

Pharmaforum

Christophe Weber

Flag link:

Positive quarter from Takeda, waiting for completion of Shire deal

Positive quarter from Takeda, waiting for completion of Shire deal

GoinPharma

Flag link:

Takeda considering sale of OTC business in Europe ($11bn)

Takeda considering sale of OTC business in Europe ($11bn)

Bloomberg

Flag link:

Takeda is ready to auction off a PhIII favorite at Shire to clear the last hurdles to a $62B buyout

Takeda is ready to auction off a PhIII favorite at Shire to clear the last hurdles to a $62B buyout

Enpoints

inflammatory bowel disease

ulcerative colitis

Crohn's Disease

Flag link:

Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week

Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week

BioSpace

BrainStorm Cell Therapeutics

Clovis Oncology

Acorda Therapeutics

Agios Pharmaceuticals

Teva Pharmaceutical

Flag link:

Pages